Market Overview:
Report Attribute | Details |
|---|---|
| Base Year | 2023 |
| Forecast Years | 2024-2034 |
| Historical Years | 2018-2023 |
Market Size in 2023 | US$ 3,589.7 Million |
Market Forecast in 2034 | US$ 11,282.5 Million |
Market Growth Rate 2024-2034 | 10.85% |
How big is the market for CAR T-cell therapy?
The CAR T-Cell Therapy market size reached a value of US$ 3,589.7 Million in 2023 and expected to reach US$ 11,282.5 Million by 2034, exhibiting a growth rate (CAGR) of 10.85% during 2024-2034.
The Chimeric Antigen Receptor (CAR) T-Cell Therapy market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the Chimeric Antigen Receptor (CAR) T-Cell Therapy market.
Request for a Sample of this Report: https://www.imarcgroup.com/chimeric-antigen-receptor-t-cell-therapy-market/requestsample
Chimeric Antigen Receptor (CAR) T-Cell Therapy Market Trends:
Chimeric antigen receptor (CAR) T-cell therapy is a cancer treatment method that requires genetically editing the T cells of the patient or the donor to create a chimeric antigen receptor that precisely targets a tumor antigen. The chimeric antigen receptor (CAR) T-cell therapy market is expanding rapidly due to numerous important reasons. Primarily, the increasing prevalence of cancer, particularly hematologic malignancies, is a major factor fueling demand for innovative and effective treatments. Furthermore, advancements in genetic engineering and biotechnology have enhanced the efficacy and safety profiles of CAR T-cell therapies, making them more appealing to both clinicians and patients.
Additionally, the regulatory environment is also becoming more favorable, with expedited review processes and breakthrough therapy designations helping to bring new treatments to the chimeric antigen receptor (CAR) T-cell therapy market. Besides this, the ongoing expansion of healthcare infrastructure, particularly in emerging markets, is improving access to advanced cancer treatments, contributing to market growth. Companies are also exploring the potential of CAR T-cell therapies beyond oncology, investigating their applications in autoimmune diseases and infectious diseases, which could open new avenues for market expansion. Consequently, the trend towards developing multi-target CAR T-cell therapies, which can address several cancer antigens simultaneously, is anticipated to drive the growth of the chimeric antigen receptor (CAR) T-cell therapy market in the coming years.
Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Chimeric Antigen Receptor (CAR) T-Cell Therapy market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current Chimeric Antigen Receptor (CAR) T-Cell Therapy marketed drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
Competitive Landscape of Key Players :
The competitive landscape of the Chimeric Antigen Receptor (CAR) T-Cell Therapy market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these Key Players:
- Juno Therapeutics
- 2seventy bio
- Janssen Biotech/Nanjing Legend Biotech
- Novartis/University of Pennsylvania
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6383&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
